Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Depreciation & Amortization (CF) (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $376000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 218.64% to $376000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 54.96% year-over-year, with the annual reading at $1.3 million for FY2025, 54.96% up from the prior year.
  • Depreciation & Amortization (CF) hit $376000.0 in Q4 2025 for Protagonist Therapeutics, up from $361000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $376000.0 in Q4 2025 to a low of $118000.0 in Q4 2024.
  • Historically, Depreciation & Amortization (CF) has averaged $246500.0 across 5 years, with a median of $242500.0 in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): plummeted 52.42% in 2024 and later skyrocketed 218.64% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $235000.0 in 2021, then increased by 8.94% to $256000.0 in 2022, then fell by 3.12% to $248000.0 in 2023, then tumbled by 52.42% to $118000.0 in 2024, then surged by 218.64% to $376000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for PTGX at $376000.0 in Q4 2025, $361000.0 in Q3 2025, and $304000.0 in Q2 2025.